Bayer and Huma expand digital heart risk tool to Saudi Arabia

Bayer and Huma Therapeutics have launched an innovative heart health screening tool in Saudi Arabia, aligning with the country's Vision 2030 healthcare transformation strategy. The tool, known as the Bayer Aspirin Heart Health Risk Assessment, evaluates an individual's risk for developing cardiovascular disease over the next decade using digital technology, without the need for invasive tests. This launch aims to address the high prevalence of cardiovascular diseases in Saudi Arabia and supports the national priority of reducing the clinical and economic burden of such diseases through prevention efforts.

The collaboration between Bayer and Huma extends beyond the heart health assessment tool, with both companies supporting additional healthcare initiatives in Saudi Arabia in line with Vision 2030 objectives. Huma has launched a diabetes care pathway within the Seha Virtual Hospital, while Bayer has committed to screening one million citizens at risk of cardiovascular disease as part of the 'Protect Your Heart' campaign in partnership with the Saudi Ministry of Health. These efforts are part of a broader strategy to leverage digital health tools and innovation to improve healthcare outcomes and foster a healthier future for the Saudi population.

The expansion of the heart health assessment tool to Saudi Arabia reflects Bayer and Huma's commitment to advancing digital health solutions globally. Beyond Saudi Arabia, the companies plan to introduce the Heart Health Risk Assessment tool to Latin America in the coming year, aiming to further contribute to preventive care efforts and promote early detection of cardiovascular diseases in other regions as well.